Aptorum Group Approves All-Stock Merger with DiamiR, Closing by Fiscal 2027
APM•On June 9, 2026, Aptorum Group shareholders approved the proposed all-stock merger with DiamiR Biosciences, advancing the transaction toward closing before fiscal 2027. Upon completion, DiamiR will become a wholly owned subsidiary, expanding Aptorum’s reach into blood-based diagnostics for neurodegenerative and brain health applications.
1. Shareholder Approval
On June 9, 2026, shareholders of both Aptorum Group and DiamiR Biosciences voted to approve the previously announced all-stock merger, achieving a critical milestone required to move the transaction toward completion.
2. Merger Terms and Timeline
Under the terms of the agreement, DiamiR Biosciences will become a wholly owned subsidiary of Aptorum Group once customary closing conditions are satisfied or waived, with both companies targeting a closing date before the end of fiscal 2027.
3. Strategic Benefits
The combined entity will integrate Aptorum’s clinical-stage biopharmaceutical assets with DiamiR’s proprietary blood-based microRNA diagnostic platform for brain health, aiming to accelerate commercialization, expand strategic partnerships, and drive sustainable growth in neurodegenerative disease testing.
